Get the Stockscreener App
0.9364
3.54%
0.032
Tevogen Bio Holdings Inc stock is traded at $0.9364, with a volume of 456.35K.
It is up +3.54% in the last 24 hours and down -15.64% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
See More
Previous Close:
$0.9044
Open:
$0.8963
24h Volume:
456.35K
Relative Volume:
0.51
Market Cap:
$184.19M
Revenue:
-
Net Income/Loss:
$52.50M
P/E Ratio:
32.18
EPS:
0.0291
Net Cash Flow:
$-4.13M
1W Performance:
-1.25%
1M Performance:
-15.64%
6M Performance:
-33.82%
1Y Performance:
+55.83%
1-Day Range:
$0.8901
$0.9439
1-Week Range:
$0.8901
$0.9788
52-Week Range:
$0.2556
$3.09
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN
Compare TVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
0.9364 | 186.68M | 0 | 52.50M | -4.13M | 0.0291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
Technical Heatmap Flags Tevogen Bio Holdings Inc. Equity Warrant for Watch2025 Key Highlights & Expert-Curated Trade Recommendations - thegnnews.com
Tevogen Bio Holdings Inc. Stock Approaches Key Moving Average2025 Biggest Moves & Daily Profit Maximizing Trade Tips - newsyoung.net
Tevogen Bio's Strategic Financing and AI-Driven R&D Catalysts: A New Paradigm in Biopharma Innovation - AInvest
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 - GlobeNewswire
Tevogen Bio Holdings Inc. Enters into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts - MarketScreener
Tevogen Bio Holdings and the Path to Revenue by 2026: A Strategic Assessment of Risk, Innovation, and Capital Efficiency - AInvest
Tevogen Bio Holdings anticipates revenue by end of 2026 - MarketScreener
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum - The Manila Times
Tevogen Delivers Stronger Second Quarter and First Half - GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement - The Manila Times
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery - GlobeNewswire
RSI and MACD Indicate Shift in Tevogen Bio Holdings Inc. Equity Warrant SentimentJuly 2025 Weekly Recap & Free Community Consensus Stock Picks - classian.co.kr
Tevogen Bio Holdings Inc. Recovery Potential Based on Technical ToolsWeekly Trend Report & Low Risk Investment Opportunities - metal.it
Custom Dashboard Highlights Tevogen Bio Holdings Inc. Equity Warrant Price Momentum2025 Market Outlook & Stepwise Trade Signal Guides - 선데이타임즈
Why Tevogen Bio Holdings Inc. stock attracts strong analyst attentionJuly 2025 PostEarnings & Verified Entry Point Detection - sisaissue.com
Tevogen Bio Highlights Undervalued Intangible Assets, Citing Proprietary IP, AI Platforms And 74% Insider Ownership - 富途牛牛
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected - GlobeNewswire
RepeatTevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology - Investing News Network
Tevogen Bio Holdings Inc. Equity Warrant At Critical Juncture — Bounce or BreakdownJuly 2025 Big Picture & AI Forecast Swing Trade Picks - beatles.ru
Tevogen Receives $1M to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - AI Insider
Tevogen Peports Plans to Increase the Target Population for TVGN 489 - MSN
Quant Strategy Flags Tevogen Bio Holdings Inc. Equity Warrant for EntrySwing Trading Plan With Smart Signals in Review - sundaytimes.kr
Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction - Benzinga
Tevogen Bio Holdings Inc. shares rise 1.53% premarket after reaffirming investor confidence and projecting $1 billion in oncology revenue. - AInvest
Tevogen Bio Oncology Reports Top-Line Revenue Forecast - GlobeNewswire
Tevogen Bio Holdings Inc. shares fall 1.53% premarket despite positive revenue forecasts and investor confidence. - AInvest
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line - GlobeNewswire
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion - GlobeNewswire
Biotech Unicorn Tevogen Bio Skyrockets from $4.2B to $10B Valuation: Inside the Massive Growth Story - Stock Titan
REPEATTevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders - GlobeNewswire
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion - The Manila Times
Tevogen Bio Projects Massive $22B Revenue From Revolutionary T Cell Therapies for Long COVID - Stock Titan
Tevogen Bio sees $1 bln revenue in launch year for oncology - MarketScreener
Biotech Revenue Breakthrough: Tevogen Bio Targets $14 Billion From Cancer and COVID Therapies - Stock Titan
Tevogen's Strategic AI and Biotech Convergence: Pioneering a New Era in Drug Development - AInvest
Tevogen Bio Holdings Expands into AI with Tevogen.AI - AInvest
Tevogen Bio Holdings Inc. Outlines Strategic Growth and Advancements in AI-Driven Healthcare Solutions - Quiver Quantitative
Tevogen's CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders. - AInvest
Beam Global to Release Q2 2025 Operating Results, Conference Call Scheduled for August 14, 2025 at 4:30 p.m. ET - The Globe and Mail
📈 Which tech stocks have recently seen an increase in institutional ownership? - AInvest
Tevogen's Explosive Institutional Investor Influx: A Signal of Biotech Breakout Potential - AInvest
Tevogen Bio Holdings Inc. shares rise 1.27% intraday after significant institutional ownership growth. - AInvest
Pinterest Q2 Earnings Miss Estimates Despite Y/Y Revenue Growth - The Globe and Mail
Tevogen Sees Significant Growth in Institutional Ownership - AInvest
5 Stocks to Buy on a Pullback - The Globe and Mail
Is Uber Still the Best Stock to Buy Now? - The Globe and Mail
P10 Holdings Reports Strong Q2 2025 Financial Results - The Globe and Mail
Targa Resources Announces $1 Billion Share Buyback - The Globe and Mail
What's Behind Marvell Technology Stock's Recent Surge? - The Globe and Mail
Tevogen sees 60% institutional ownership increase, led by Vanguard and BlackRock. - AInvest
Published on: 2025-08-08 09:01:56 - beatles.ru
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):